Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.82 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451398 | 0.91 | PTGS1 (1.00) | PTGS1PTGS2PDPK1NR3C2MAPT | |
| SCHEMBL27602805 | 0.85 | PTGS1 (0.82) | PTGS1PTGS2PDPK1MAPTTP53 | |
| SCHEMBL6175728 | 0.84 | PTGS1 (0.58) | PTGS1PTGS2PDPK1NR3C2CYP2C9 | |
| SCHEMBL5344449 | 0.84 | PTGS1 (0.80) | PTGS1PTGS2PDPK1MAPTCYP2C9 | |
| SCHEMBL6610915 | 0.84 | PTGS1 (0.80) | PTGS1PTGS2PDPK1MAPTCYP2C9 | |
| SCHEMBL27602802 | 0.84 | PTGS2 (0.86) | PTGS1PTGS2PDPK1MAPTCYP2C9 | |
| Sulfamide SCHEMBL7139961 | 0.82 | PTGS1 (0.83) | PTGS1PTGS2PDPK1CYP2C9 | |
| SCHEMBL6097021 | 0.82 | PTGS2 (0.64) | PTGS1PTGS2PDPK1CYP2C9 | |
| SCHEMBL2850104 | 0.82 | PTGS2 (0.85) | PTGS1PTGS2CYP2C9 | |
| Carbamic Acid SCHEMBL5861049 | 0.81 | PTGS1 (0.70) | PTGS1PTGS2PDPK1NR3C2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790725-B2 | Thiazolidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| CN-100341862-C | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORP (JP) | 2007-10-10 | — | — | CN | disclosed |
| CN-1606549-A | Thiazolidine derivative and medical application thereof | MITSUBISHI PHARMA CORP (JP) | 2005-04-13 | — | — | CN | disclosed |
| EP-1426366-A1 | THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | PTGS1 1656/4885PTGS2 2349/4885PDPK1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.